Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243s–9s.
Article
PubMed
Google Scholar
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O, ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.
Article
PubMed
CAS
Google Scholar
Loblaw DA, Wu JS, Kirkbride P, Panzarella T, Smith K, Aslanidis J, Warde P. Pain flare in patients with bone metastases after palliative radiotherapy – a nested randomized control trial. Support Care Cancer. 2007;15:451–5.
Article
PubMed
Google Scholar
Chow E, Hoskin P, van der Linden Y, Bottomley A, Velikova G. Quality of life and symptom end points in palliative bone metastases trials. Clin Oncol (R Coll Radiol) 2006;18:67–69.
Langer C, Hirsh V. Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates. Lung Cancer. 2010;67:4–11.
Article
PubMed
Google Scholar
Plunkett TA, Smith P, Rubens RD. Risk of complications from bone metastases in breast cancer. Implications for management Eur J Cancer. 2000;36:476–82.
Article
PubMed
CAS
Google Scholar
Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M. Zoledronic Acid Prostate Cancer Study Group: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879–82.
Article
PubMed
CAS
Google Scholar
von Moos R, Sternberg C, Body JJ, Bokemeyer C. Reducing the burden of bone metastases: current concepts and treatment options. Support Care Cancer. 2013;21:1773–83.
Article
PubMed
Google Scholar
Katzer A, Meenen NM, Grabbe F, Rueger JM. Surgery of skeletal metastases. Arch Orthop Trauma Surg. 2002;122:251–8.
Article
PubMed
Google Scholar
Rubens RD. Bone metastases – the clinical problem. Eur J Cancer. 1998;34:210–3.
Article
PubMed
CAS
Google Scholar
Body JJ, Chevalier P, Gunther O, Hechmati G, Lamotte M. The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium. J Med Econ. 2013;16:539–46.
Article
PubMed
Google Scholar
Hechmati G, Cure S, Gouépo A, Hoefeler H, Lorusso V, Lüftner D, Duran I, Garzon-Rodriguez C, Ashcroft J, Wei R, Ghelani P, Bahl A. Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study. J Med Econ. 2013;16:691–700.
Article
PubMed
CAS
Google Scholar
Lothgren M, Ribnicsek E, Schmidt L, Habacher W, Lundkvhist J, Pfeil AM, Biteeva I, Vrouchou P, Bracco A. Cost per patient and potential budget implications of denosumab compared with zoledronic acid in adults with bone metastases from solid tumours who are at risk of skeletal-related events: an analysis for Austria, Sweden and Switzerland. Eur J Hosp Pharm. 2013;20:227–31.
Article
Google Scholar
Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88:1082–90.
Article
PubMed
CAS
Google Scholar
Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 2004;100:2613–21.
Article
PubMed
CAS
Google Scholar
Clemons M, Gelmon KA, Pritchard KI, Paterson AH. Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art. Curr Oncol. 2012;19:259–68.
Article
PubMed
PubMed Central
CAS
Google Scholar
Roche: Bondronat® summary of product characteristics. 2015. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000101/human_med_000678.jsp&mid=WC0b01ac058001d124. [Accessed 26 Apr 2016].
Google Scholar
Novartis: ZOMETA® summary of product characteristics. 2016. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000336/human_med_001182.jsp&mid=WC0b01ac058001d124 [Accessed 26 Apr 2016].
Google Scholar
Hospira: Pamidronate disodium prescribing information. 2016. https://www.medicines.org.uk/emc/medicine/21443. [Accessed 26 Apr 2016].
Google Scholar
Bayer: BONEFOS® summary of product characteristics. 2016. https://www.medicines.org.uk/emc/medicine/311. [Accessed 26 Apr 2016].
Google Scholar
Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813–22.
Article
PubMed
PubMed Central
CAS
Google Scholar
Henry D, Vadhan-Raj S, Hirsh V, von Moos R, Hungria V, Costa L, Woll PJ, Scagliotti G, Smith G, Feng A, Jun S, Dansey R, Yeh H. Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer. 2014;22:679–87.
Article
PubMed
Google Scholar
Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer. 2012;48:3082–92.
Article
PubMed
CAS
Google Scholar
Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28:5132–9.
Article
PubMed
CAS
Google Scholar
von Moos R, Body JJ, Egerdie B, Stopeck A, Brown JE, Damyanov D, Fallowfield LJ, Marx G, Cleeland CS, Patrick DL, Palazzo FG, Qian Y, Braun A, Chung K. Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer. 2013;21:3497–507.
Article
PubMed
Google Scholar
Arellano J, Hauber AB, Mohamed AF, Gonzalez JM, Collins H, Hechmati G, Gatta F, Qian Y. Physicians' preferences for bone metastases drug therapy in the United States. Value Health. 2015;18:78–83.
Article
PubMed
Google Scholar
Arellano J, González JM, Qian Y, Habib M, Mohamed AF, Gatta F, Hauber AB, Posner J, Califaretti N, Chow E. Physician preferences for bone metastasis drug therapy in Canada. Curr Oncol. 2015;22:e342–8.
Article
PubMed
PubMed Central
CAS
Google Scholar
Marshall D, Bridges JF, Hauber B, Cameron R, Donnalley L, Fyie K, Johnson FR. Conjoint Analysis Applications in Health – How are Studies being Designed and Reported?: An Update on Current Practice in the Published Literature between 2005 and 2008. Patient. 2010;3:249–56.
Article
PubMed
Google Scholar
Mohamed AF, Hauber AB, Neary MP. Patient benefit-risk preferences for targeted agents in the treatment of renal cell carcinoma. Pharmacoeconomics. 2011;29:977–88.
Article
PubMed
Google Scholar
Hensher DA, Rose JM, Greene WH. Applied choice analysis: a primer. Cambridge: Cambridge University Press; 2005.
Book
Google Scholar
Louviere JJ, Hensher DA, Swait JD. Stated choice methods: analysis and applications. Cambridge: Cambridge University Press; 2000.
Book
Google Scholar
Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, Johnson FR, Mauskopf J. Conjoint analysis applications in health – a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14:403–13.
Article
PubMed
Google Scholar
Amgen: XGEVA® prescribing information. 2016. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125320Orig1s177lbl.pdf. [Accessed 22 Apr 2016].
Google Scholar
Novartis: ZOMETA® prescribing information. 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021223s034lbl.pdf. [Accessed 22 Apr 2016].
Google Scholar
Amgen: XGEVA® summary of product characteristics. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002173/WC500110381.pdf. [Accessed 26 Apr 2016].
Google Scholar
Jagdev SP, Purohit P, Heatley S, Herling C, Coleman RE. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol. 2001;12:1433–8.
Article
PubMed
CAS
Google Scholar
Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med. 1999;246:67–74.
Article
PubMed
CAS
Google Scholar
Swait J, Louviere J. The Role of the Scale Parameter in the Estimation and Use of Multinomial Logit Models. J Mark Res. 1993;30:305–14.
Article
Google Scholar
Train KE. Discrete choice methods with simulation. Cambridge: Cambridge University Press; 2003.
Book
Google Scholar
Train KE, Sonnier G. Mixed logit with bounded distributions of correlated partworths. In: Scarpa R, Alberini A, editors. Applications of simulation methods in environmental and resource economics, vol. 6. Dordrecht: Springer; 2005.
Google Scholar
Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567–75.
Article
PubMed
Google Scholar
Polascik TJ, Mouraviev V. Zoledronic acid in the management of metastatic bone disease. Ther Clin Risk Manag. 2008;4:261–8.
Article
PubMed
PubMed Central
CAS
Google Scholar
Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carrière P. Dansey Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23:1341–7.
Article
PubMed
CAS
Google Scholar
Hechmati G, Arellano J, Mohamed AF, Hauber AB, Qian Y, Gatta F, Haynes I, Bahl A. Patients' preferences for attributes of bone metastases treatments in France, Germany and the United Kingdom. Poster presented at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO), Amsterdam, Netherlands, 2013.
Henry DH, von Moos R, Body J-J, Rider A, De Courcy J, Murray G, Bhowmik D, Gatta F, Arellano J, Hechmati G, Roberts Z, Qian Y Bone targeting agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the US Poster presented at the 2015 Breast Cancer Symposium, San Francisco, CA, USA, 2015.